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ABSTRACT 
We evaluated the impact of clinical and molecular characteristics on overall survival (OS) in 108 
patients with indolent (n=41) and advanced SM (advSM, n=67). Organomegaly was measured 
by magnetic resonance imaging (MRI)-based volumetry of liver and spleen. In multivariate 
analysis of all patients, an increased spleen volume ≥450mL (hazard ratio [HR], 5.2; 95% 
confidence interval [CI], [2.1-13.0]; P=0.003) and an elevated alkaline phosphatase (AP; HR 5.0 
[1.1-22.2]; P=0.02) were associated with adverse OS. The 3-year OS was 100%, 77%, and 39%, 
respectively (P<0.0001), for patients with 0 (low-risk, n=37), 1 (intermediate-risk, n=32) or 2 
(high-risk, n=39) parameters. For advSM patients with fully available clinical and molecular 
data (n=60), univariate analysis identified splenomegaly ≥1200mL, elevated AP and mutations in 
the SRSF2/ASXL1/RUNX1 (S/A/R) gene panel as significant prognostic markers. In multivariate 
analysis, mutations in S/A/R (HR, 3.2 [1.1-9.6]; P=0.01) and elevated AP (HR 2.6 [1.0-7.1]; 
P=0.03) remained predictive adverse prognostic markers for OS. The 3-year OS was 76% and 
38%, respectively (P=0.0003), for patients with 0-1 (intermediate-risk, n=28) or 2 (high-risk, 
n=32) parameters. We conclude that splenomegaly, elevated AP and mutations in the S/A/R gene 
panel are independent of the WHO classification and provide the most relevant prognostic 
information in SM patients. 
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INTRODUCTION 
Systemic mastocytosis (SM) comprises a group of rare myeloid neoplasms characterized by 
accumulation of mast cells (MC) in various tissues, predominantly bone marrow (BM), skin and 
visceral organs. Depending on the involvement of other hematopoietic lineages and disease-related 
organ damage, SM can be categorized into indolent SM (ISM) and advanced SM (advSM). AdvSM 
includes patients with SM and associated clonal hematologic non-mast cell lineage disease (SM-
AHNMD), aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL).
1-4
 In contrast to 
ISM, advSM has a poor prognosis with median survival between few months in patients with MCL 
and less than 2-4 years in patients with SM-AHNMD and ASM.
5
 
 
Activating mutations in the receptor tyrosine kinase KIT, usually KIT D816V, are pathogenetically 
relevant somatic point mutations, detected in >80-90% of patients with SM.
6,7
 The multi-lineage 
expansion by KIT D816V and the KIT D816V allele burden (AB) have an important impact on disease 
phenotype and prognosis.
6,8-10
 Furthermore, the presence and number of molecular aberrations, e.g. in 
SRSF2, ASXL, or RUNX1 (S/A/R gene panel), have a strong adverse impact on disease phenotype and 
OS in patients with advSM..
9,11
 
 
One of several WHO criteria to classify SM includes enlargement of visceral organs, e.g. spleen, liver, 
or lymph nodes. In addition to high MC burden in the bone marrow (BM), elevated serum tryptase  
> 200µg/L and signs of dysplasia or myeloproliferation in the BM, organomegaly is an accepted B-
finding which supports the diagnosis of SSM. Signs of organ damage (C-findings), e.g. cytopenia(s), 
hepatomegaly with impaired liver function, palpable splenomegaly with signs of hypersplenism, 
malabsorption with significant hypoalbuminemia and/or significant weight loss, support the diagnosis 
of advSM. However, only little is yet known about the prognostic impact of clinical and hematological 
characteristics such as B- and C-findings.  
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We therefore sought to evaluate the impact of hepatomegaly and splenomegaly, as objectively 
measured by magnetic resonance imaging (MRI)-based volumetry, as well as other known clinical and 
morphological characteristics, on prognosis in SM.  
 
 
PATIENTS AND METHODS 
Diagnosis and classification of SM 
The diagnosis of SM was established according to the WHO classification: indolent SM (ISM, n=41) 
and advSM (n=67; ASM, n=5; SM-AHNMD, n=46; MCL, n=7; MCL-AHNMD, n=9).
1,5,12
 Fifty-five 
patients had an AHNMD, including chronic myelomonocytic leukemia (CMML, n=19), 
myelodysplastic/myeloproliferative neoplasm unclassified (MDS/MPN-U, n=19), chronic eosinophilic 
leukemia (CEL, n=9), acute myeloid leukemia (AML, n=5), and myelofibrosis (MF, n=3). BM 
biopsies were evaluated by reference pathologists of the European Competence Network on 
Mastocytosis, ECNM (H.-P.H. and K.S.). Cytoreductive treatment in 61/67 patients with advSM 
included midostaurin (n=14), cladribine (n=5), cladribine following midostaurin or vice versa (n=16), 
midostaurin (n=6) or cladribine (n=2) followed by intensive chemotherapy with (n=2) or without 
(n=6) allogeneic stem cell transplantation. Ten patients were treated with hydroxyurea (n=6), nilotinib 
(n=2) or decitabine (n=2).  
 
The diagnosis of ASM was based on the presence of one or more C-findings (cytopenia with an 
absolute neutrophil count < 1 x 10
9
/L, hemoglobin < 10.0 g/dL, platelets < 100 x 10
9
/L, hepatomegaly 
with impaired liver function, palpable splenomegaly with signs of hypersplenism, malabsorption with 
significant hypoalbuminemia and/or significant weight loss > 10% over the last 6 months).
2,5,13
 
Diagnosis of MCL was based on the presence of at least 20% mast cells in BM smears with or without 
C-findings. The diagnosis AHNMD was established by evaluating peripheral blood (PB, e.g. 
monocytosis and/or eosinophilia) and BM by morphology, histology and immunohistochemistry using 
WHO criteria and a panel of standard-markers, depending on the suspected AHNMD subtype.  
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In all patients with significant eosinophilia (> 1 x 10
9
/L), the presence of FIP1L1-PDGFRA or other 
rearrangements of PDGFRA, PDGFRB, or FGFR1 were excluded by cytogenetics (no rearrangement 
of 4q12, 5q31-33 or 8p11), RT-PCR (no fusion gene), and/or FISH analysis (no rearrangement). The 
study design adhered to the tenets of the Declaration of Helsinki and was approved by the institutional 
review board of the Medical Faculty of Mannheim, University of Heidelberg, as part of the ‘German 
Registry on Disorders of Eosinophils and Mast Cells’. All patients gave written informed consent.  
 
Gene mutation analyses 
Analysis for mutations in KIT and quantitative assessment of the KIT D816V expressed allele burden 
(EAB) were performed by allele-specific quantitative real-time polymerase as described.
6
 Next-
generation deep amplicon sequencing by 454 FLX amplicon chemistry (Roche, Penzberg, Germany) 
was performed to investigate 18 genes recurrently mutated in myeloid neoplasms as previously 
described.
9
 
 
Magnetic resonance imaging (MRI)-based volumetry  
All examinations were performed on a 1.5T whole-body MRI system (Magnetom Avanto, Siemens 
Healthcare, Erlangen, Germany). Volume measurements of liver and spleen were performed by a 
resident (J.C.) using a FDA-approved, commercially available, software (Aycan OsiriX pro v.2.06 64-
Bit). Results were verified by a board-certified radiologist (D.H.). For volume measurements 
gadolinium-based, contrast-enhanced, axial T1-weighted sequences were utilized that covered both 
organs (T1 vibe fs tra; acquisition matrix 384 x 225; slice thickness 3mm; FoV 296 x 379mm). 
Regions of interest were drawn surrounding the surface of each organ in all slices. Subsequently, 
volume calculation was performed automatically by the software by interpolating and summing up the 
planimetric results to a single volume. The abdominal MRI also allowed identification and 
measurement of ascites and abdominal lymphadenopathy (LNA).  
 
Statistical analyses 
All statistical analyses considered clinical and laboratory parameters obtained at time of MRI. OS 
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analysis was considered from the date of MRI to date of death or last contact. Pearson correlation 
analysis was performed for the correlation between two parameters, e.g. there was a positive 
correlation if both parameters had a tendency to increased levels and a negative correlation if one 
parameter had the tendency to increase, the other to decrease. Differences in the distribution of 
continuous variables between categories were analyzed by either Mann-Whitney test (for comparison 
of two groups) or Kruskal-Wallis test (for comparison of three groups). For categorical variables, 
Fishers’s exact test was used. For univariate (including almost all SM-related parameters) and 
multivariate analyses, receiver operating characteristic (ROC) curve with a time-dependent survival 
probability were used to identify optimal cut-off points. OS probabilities were estimated with the 
Kaplan-Meier method and compared by the log-rank test in univariate analysis. For the estimation of 
hazard ratios (HRs) and multivariate analysis, the Cox proportional hazard regression model was used 
(backward selection). P-values < 0.05 (two-sided) were considered significant. There was no 
adjustment for multiple testing as all analyses were explorative. SPSS version 22.0.0 (IBM 
Corporation, Armonk, NY, USA) and SAS version 9.2 (SAS Institute, Cary, NC, USA) were used for 
statistical analysis. 
 
 
RESULTS 
Patients 
The study group included 108 patients with a median age of 64 years (range 27-82). Relevant SM-
associated disease characteristics are presented in Table 1. The median BM MC infiltration, 
determined by BM immunohistochemistry, was 20% (range 5-95), and the median serum tryptase was 
127 µg/L (range 13-951, normal value < 11.4). Ninety-eight percent (106/108) of the patients were 
KIT D816V
 
positive, one patient was KIT D816H positive, and one patient was negative for KIT 
mutations. The median KIT D816V EAB in PB (available in 101/108 patients) was 22% (range 1-99).  
 
Median blood counts were as follows: leukocytes 8.0 × 10
9
/L, hemoglobin 12.3 g/dL (< 10 g/dl in 
22% of patients), platelets 181 × 10
9
/L (< 100 × 10
9
/L in 25% of patients), monocytes 0.5 x 10
9
/L (> 1 
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x 10
9
/L in 21% of patients) and eosinophils 0.2 x 10
9
/L (> 1 x 10
9
/L in 19% of patients). Non-
hematologic C-findings included hypoalbuminemia (< 35 g/L) in 26% of patients, and elevated AP (> 
150 U/L; normal value 40-150) in 41% of patients. Median observation time from the date of MRI was 
26 months (range 1-79); 36/108 patients (33%) died in the observation period. The 3-year OS 
probability of all patients was 64%, with a median OS of 5.4 years.  
 
Magnetic resonance imaging (MRI) findings  
In advSM, MRI was performed within 6 months of primary diagnosis in 82% of patients, and in the 
remaining patients within 12 months of diagnosis. The median volumes of liver and spleen were 2035 
mL (range 1034-4265) and 540 mL (range 92-3193), respectively. ROC-analysis identified a spleen 
volume of 450 mL as optimal volumetric thresholds for all patients and 1200 mL for patients with 
advSM only. The optimal cut-off for hepatomegaly was 2400 mL for all patients. 
 
Overall, MRI-documented hepatomegaly was observed in 31/108 patients (29%), and splenomegaly in 
67/108 patients (62%). Splenomegaly was mild (≥ 450 mL and <1200 mL) in 43/67 patients (64%) 
and marked (≥ 1200 mL) in 24/67 patients (36%). Ascites and LNA were detected in 37/108 patients 
(34%), and 52/108 patients (48%), respectively (Table 1). Pearson’s analyses showed a strong positive 
correlation between spleen and liver volume or liver volume and ascites. A strong negative correlation 
was observed between spleen volume and platelets/hemoglobin or ascites and albumin. Other 
correlations are shown in Figure 1.  
 
Correlation between spleen volume and clinical phenotype 
In ISM (n=41, 38% of all patients), splenomegaly was observed in 8/41 patients (20%). In contrast, 
splenomegaly (mild or marked) was present in 59/67 (88%) patients with advSM. The comparison 
between no splenomegaly and any type of splenomegaly (mild or marked) revealed significant 
differences in almost all parameters, including age, B-findings, C-findings, BM MC infiltration, serum 
tryptase, and KIT D816V EAB (Table 1). When patients with mild and marked splenomegaly were 
compared, the median platelet count, elevated AP (> 150 U/L), liver volume, and ascites were 
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significantly different, indicating a more aggressive phenotype in patients with marked splenomegaly 
(Table 1). 
 
Impact of spleen volume on overall survival 
The spleen volume was significantly associated with adverse OS. Pairwise significantly different OS 
probabilities were observed for the comparison between no splenomegaly (n=41) vs. any 
splenomegaly (n=67, median not reached vs. 3.1 years, HR 10.7 [2.6-44.7], P < 0.0001), no 
splenomegaly (n=41) vs. mild splenomegaly (n=43, HR 6.9 [1.6-30.1], P = 0.003), no splenomegaly 
vs. marked splenomegaly (n=24, HR 33.9 [4.5-255.4], P < 0.0001), and mild splenomegaly vs. marked 
splenomegaly (HR 2.6 [1.3-5.3], P = 0.005). The 3-year OS was 98%, 68%, and 30% for patients with 
no splenomegaly, mild splenomegaly, and marked splenomegaly, respectively (Table 1, Figure 2A). 
 
Correlation between liver volume, clinical phenotype and overall survival 
Hepatomegaly was observed in 3/41 patients (7%) and 28/67 patients (42%) with ISM and advSM, 
respectively. The comparison between no hepatomegaly and hepatomegaly revealed significant 
differences regarding almost all parameters, including C-findings, BM MC infiltration, serum tryptase, 
and KIT D816V EAB. Almost all patients (29/31, 94%) with hepatomegaly had any form of 
splenomegaly (mild or marked) but not vice versa.  
 
Univariate and multivariate analyses of SM-related parameters 
The results of univariate analyses for multiple clinical and laboratory variables concerning OS were 
significant as follows: age ≥ 65 (HR 4.1 [1.9-9.0], P = 0.0002), cytopenia (hemoglobin < 10 g/dL 
and/or platelets < 100 x 10
9
/L, HR 4.5 [2.2-9.2], P < 0.0001), ascites (HR 3.2 [1.6-6.5], P = 0.004), 
elevated AP (> 150 U/L, HR 8.3 [3.4-19.9], P < 0.0001), hypoalbuminemia (HR 2.7 [1.4-5.2], P = 
0.002), markedly elevated serum tryptase (> 200 µg/L, HR 3.6 [1.7-7.3], P = 0.0002), hepatomegaly 
(> 2400 mL, HR 2.5 [1.3-4.9], P = 0.007), any splenomegaly (≥ 450 mL, HR 10.7 [2.6-44.7], P < 
0.0001), LNA (HR 2.2 [1.1-4.6], P = 0.03), multi-lineage expansion (monocytes  > 1 x 10
9
/L and/or 
eosinophils > 1 x 10
9
/L, HR 3.5 [1.8-6.7], P  < 0.0001) and KIT D816V EAB in PB > 30% (HR 3.3 
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[1.7-6.5], P = 0.0003). In multivariate analyses including all clinical and hematological variables with 
significant prognostic value in univariate analyses, only splenomegaly ≥ 450 mL (HR 5.2 [2.1-13.0], P 
= 0.003) and elevated AP (HR 5.0 [1.1-22.2], P = 0.02) remained independent poor risk factors for OS 
(Table 2A, Figure 2A). Regarding the comparison of the disparate WHO subgroups, e.g. ISM vs. 
advSM, ASM vs. MCL, ASM vs. SM-AHNMD, MCL vs. SM-AHNMD, only ISM vs. advSM (P < 
0.0001) was significant in univariate analysis, but was not significant in multivariate analyses. 
 
In univariate analyses of 60/67 patients with advSM and available mutation status of the S/A/R gene 
panel, marked splenomegaly (≥ 1200 mL, HR 3.0 [1.4-6.4], P = 0.002), elevated AP (> 150 U/L, HR 
3.6 [1.6-9.3], P = 0.006) and mutations in the S/A/R gene panel (HR 4.3 [1.5-12.4], P = 0.003) were 
significant with regard to OS. In multivariate analysis, elevated AP (HR 2.6 [1.0-7.1], P = 0.03) and 
mutations in the S/A/R gene panel (HR 3.2 [1.1-9.6], P = 0.01) remained independent poor risk factors 
for OS (Table 2B, Figure 2B).  
 
Risk stratification 
The risk stratification was designed based on the two independent parameters identified in multivariate 
analysis, attributing points according to their rounded HR value (Table 2A): 0 point (low-risk, n = 37) 
for patients without splenomegaly and normal AP, 1 point (intermediate-risk, n = 32) for patients with 
any splenomegaly or elevated AP, and 2 points (high-risk, n = 39) (Figure 3A) for patients with any 
splenomegaly and elevated AP. Thus, 39/67 (58%) patients with advSM were classified as high-risk 
and 28/67 (42%) were classified as low-/intermediate-risk (Figure 4A). The median number of C-
findings was significantly higher in high-risk patients. For the cases with available DNA for NGS 
(74/108, 69%), there was a significantly higher incidence of mutations in the S/A/R gene panel in 
intermediate- (12/24, 50%) and high-risk (28/35, 80%) patients as compared to low-risk patients 
(0/15) (P < 0.0001). The 3-year OS probabilities of patients with low-, intermediate- and high-risk 
were 100%, 77%, and 39%, respectively (P < 0.0001, Table 3A, Figure 3A). 
 
In the subgroup of patients with advSM and available mutation status of the S/A/R gene panel, a 
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prognostic model was established based on the multivariate analysis (Table 2B): 0-1 point 
(intermediate-risk, n=28) for patients with normal AP and no mutation in the S/A/R gene panel or with 
elevated AP or a mutation in the S/A/R gene panel; 2 points (high-risk, n=32) for patients with 
elevated AP and mutations in the S/A/R gene panel. Thus, 28/60 (47%) patients with advSM were 
classified as intermediate-risk and 32/60 (53%) patients were classified as high-risk (Figure 4B). 
Furthermore, there was a significant correlation between massive splenomegaly and high-risk patients 
because 17/21 (81%) patients with massive splenomegaly were classified as high-risk (P = 0.003). The 
median OS probabilities of patients with high- and intermediate-risk were 24 months and not reached 
with a 3-year OS of 38% and 76%, respectively (P = 0.0003, Table 3B, Figure 3B).  
 
 
DISCUSSION 
On basis of univariate and multivariate analyses, we demonstrate that splenomegaly, elevated AP and 
mutations in the S/A/R gene panel are strong and independent adverse prognostic parameters for OS in 
patients with SM. Importantly these factors are independent of the WHO classification, and delineate 
new risk categories for patients with indolent and advSM.      
 
Splenomegaly is one of the most prominent clinical characteristics in patients with MPN and is 
included in widely applied prognostic scoring systems, e.g. in chronic myeloid leukemia.
14-16
 
Splenomegaly is not included in established prognostic scoring systems for MF but data from 
ruxolitinib-based clinical trials have demonstrated an adverse prognostic impact of the initial spleen 
volume and the lack of spleen volume reduction on treatment.
17-19
 In MF, these associations were only 
established because the spleen volume was accurately measured by volumetry through computer 
tomography (CT) or MRI. 
 
Splenomegaly and/or hepatomegaly and the related organ damage are also considered as clinically 
relevant parameters in patients with SM. Although splenomegaly is not part of the WHO diagnostic 
criteria, it is an important criterion for the classification of SM through B- and C-findings as well as 
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identifying disease progression. However, the prognostic value of splenomegaly has not yet been 
thoroughly evaluated.  Marked reduction of spleen volume as assessed by CT/MRI has recently also 
been reported for patients with advSM on midostaurin (PKC412), rendering it a valid and reliable 
parameter for the assessment of response to treatment. Accordingly, an IWG-MRT (ELN and ECNM) 
expert panel included spleen response in MF and SM in their response criteria. The panel recognized 
the highly subjective nature of the assessment of spleen and liver size by physical examination, and 
therefore recommended objective confirmation by CT/MRI.
20,21
 
 
In comparison to splenomegaly, hepatomegaly was significantly less frequently observed in patients 
with advSM, and only rarely in ISM. Of note, hepatomegaly was strongly associated with the presence 
of splenomegaly but not vice versa. Low albumin, increased liver enzymes and/or portal hypertension 
with splenomegaly and ascites characterize hepatomegaly with dysfunction of the liver. However, 
little is known about distinct differences between the various laboratory parameters, e.g. albumin, 
AST, ALT, AP, GGT and bilirubin.
22
 In our patient cohort, AST, ALT, and bilirubin were only 
elevated in a minority of patients while elevated AP and to a lesser extent also elevated GGT were 
identified in the vast majority of patients with advSM. In subsequent analyses, elevated AP had a 
significantly stronger impact on OS as compared to elevated GGT. Although the associated increase of 
AP and GGT already indicated the source of AP being hepatic but not osseous, AP isoenzyme 
analyses were performed in 25 patients proving the predominant hepatic origin in 24/25 patients. In 
addition, all 9 patients with histologically confirmed MC infiltration had an elevated AP (data not 
shown). 
 
We have recently shown the strong adverse impact of mutations in the S/A/R gene panel on OS in 
patients with advSM.
11
 We therefore included mutation profiles in our analyses and delineated  
intermediate- and high-risk subgroups of advSM patients based on elevated AP and S/A/R mutations. 
An SM patient at highest-risk (median survival of 24 months) is characterized by presence of an 
AHNMD, marked splenomegaly, elevated AP and mutations in the S/A/R gene panel. Of note, all 
these parameters are easily accessible and serial measurements may thus assist in determining 
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responses to anti-neoplastic therapy.
23
 Because patient numbers are limited, we are aware of that 
parameters that were excluded in the current model may become more significant in larger series. 
 
In conclusion, splenomegaly, elevated AP and mutations in the S/A/R gene panel provide highly 
relevant prognostic information for all subvariants of SM, independently of other clinical, 
hematological and laboratory parameters and also the WHO classification. Similar to other subtypes of 
myeloid neoplasms, it is likely that clinical and molecular markers complement each other and will 
have major implications on forthcoming prognostic scoring systems on the basis of larger patient 
cohorts, such as the dataset of the ECNM registry, with the long-term objective to develop an IPSS for 
patients with SM.   
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FIGURE LEGENDS 
Figure 1: The heat map displays correlations between two individual parameters. Colors were 
assigned on basis of the value of the *Pearson's correlation coefficient (r). E.g., a strong positive 
correlation (the other variable has a tendency to increase, in blue) was observed between spleen 
volume and liver volume or liver volume and ascites while a strong negative correlation (the other 
variable has a tendency to decrease, in red) was observed between spleen volume and 
platelets/hemoglobin or between ascites and albumin. AB, allele burden; AP, alkaline phosphatase; 
Hb, hemoglobin; LNA, lymphadenopathy; MC, mast cell infiltration; MLE, multi-lineage expansion; 
PLT, platelets. **All correlations are statistically significant with the exception of the correlation 
between LNA and tryptase.  
 
Figure 2: (A) Kaplan-Meier estimates of overall survival (OS) of patients depending on the spleen 
volume and alkaline phosphatase (AP) in 108 patients with systemic mastocytosis (SM): spleen 
volume < 450 mL (n=41, blue line) vs. spleen volume ≥ 450 mL and < 1200 mL (n=43, yellow line) 
vs. spleen volume ≥ 1200 mL (n=24, red line); normal AP (≤ 150 U/L, n=64, blue line) and elevated 
AP (> 150 U/L, n=44, red line). (B) Kaplan-Meier estimates of OS of patients depending on the spleen 
volume and AP in 60 patients with advanced SM and known mutation profile in the 
SRSF2/ASXL1/RUNX1 (S/A/R) gene panel; spleen volume < 1200 mL (n=39, yellow line) vs. spleen 
volume ≥ 1200 mL (n=21, red line); normal AP (≤ 150 U/L, n=22, blue line) vs. elevated AP (> 150 
U/L, n=38, red line). Significantly different OS probabilities were observed for the pairwise 
comparison. The P-values refer to log-rank tests and the HR (hazard ratio) is presented together with 
the 95% confidence interval.  
 
Figure 3: (A) Kaplan-Meier estimates of overall survival (OS) depending on the independent 
prognostic markers (alkaline phosphatase [AP] and spleen volume) in multivariate analyses of 108 
systemic mastocytosis (SM) patients: low-risk (n=37, blue line), intermediate-risk (n=32, yellow line) 
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and high-risk (n=39, red line). (B) Kaplan-Meier estimates of OS depending on the independent 
prognostic markers (AP and mutations in the SRSF2/ASXL1/RUNX1 [S/A/R] gene panel) in 
multivariate analyses of 60 with advanced SM: intermediate-risk (n=28, yellow line) and high-risk 
(n=32, red line). Pairwise significantly different OS probabilities were observed for the comparison 
between each groups. The P-values refer to log-rank tests and the HR (hazard ratio) is presented 
together with the 95% confidence interval.  
 
Figure 4: (A) Left column: the WHO based classification of 108 patients with indolent systemic 
mastocytosis (SM) (n=41) and advanced SM (n=67; aggressive SM [ASM], mast cell leukemia 
[MCL], SM with associated hematologic non-mast cell lineage disorder [SM-AHNMD] and MCL-
AHNMD). Right column: advanced SM patients (n=67) were stratified into low- (n=5), intermediate- 
(n=23) and high-risk (n=39) according to overall survival (OS). (B) Left column: the WHO based 
classification of 60/67 patients with advanced SM and known mutation profile in the 
SRSF2/ASXL1/RUNX1 (S/A/R) gene panel. Right column: advanced SM patients were stratified into 
intermediate- (n=28) and high-risk (n=32) regarding OS.  
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Table 1: Clinical, laboratory and magnet resonance imaging (MRI) derived
# 
volumetric analysis and findings of 108 patients with systemic mastocytosis, stratified by spleen 
volume < 450 mL (no splenomegaly), ≥ 450 mL and < 1200 mL (mild splenomegaly) or ≥ 1200 mL (marked splenomegaly). 
*The P-values refer to the Mann–Whitney U test, Fisher’s exact test or the **log-rank tests comparing patients with spleen volume < 450 mL and ≥ 450 mL or ≥ 450 mL < 1200 
mL and ≥ 1200 mL.  ***1 lymph node > 10 mm or > 10 lymph nodes < 10 mm. 
#
MRI derived
 
volumetric analysis and findings. Abbreviations: AHNMD, associated hematologic 
non-mast cell lineage disease; ASM, aggressive SM; EAB, expressed allele burden; ISM, indolent SM; MC, mast cells; MCL, mast cell leukemia; MRI, magnet resonance 
imaging; n.k., not known; n.s., not significant; OS, overall survival; PB, peripheral blood; SM, systemic mastocytosis. 
Variables 
All patients 
(n = 108) 
Spleen volume 
< 450 mL  
(n = 41) 
Spleen volume 
≥ 450 mL and  
< 1200 mL 
(n = 43) 
Spleen volume 
≥ 1200 mL 
(n = 24) 
P* 
Spleen volume < 
450 mL vs.  
≥ 450 mL 
P* 
Spleen volume  
≥ 450 mL and  
< 1200 mL vs.  
≥ 1200 mL 
Age, in years, median (range) 64 (27-82) 50 (34-81) 69 (27-82) 71 (46-81) < 0.0001
 
n.s. 
Male, n (%) 57 (53) 16 (40) 25 (58) 16 (67) 0.01 n.s. 
Diagnosis       
ISM, n (%) 41 (37) 33 (81) 7 (16) 1 (4) < 0.0001 n.s. 
ASM, n (%) 5 (5) 3 (7) 2 (5)  0 n.s. n.s. 
MCL, n (%) 7 (6) 0 6 (14) 1 (4) 0.04 n.s. 
SM-AHNMD, n (%) 46 (43) 3 (7) 27 (63) 16 (67) < 0.0001 n.s. 
MCL-AHNMD, n (%) 9 (8) 1 (2) 0 8 (33) n.s. 0.0001 
C-findings       
Hemoglobin, g/dL; median (range) 12.3 (6.8-15.6) 13.7 (9.6-15.6) 11.2 (7.5-15.1) 11.1 (6.8-13.7) < 0.0001 n.s. 
 < 10
 
g/dL, n (%) 24 (22) 1 (2) 14 (33) 9 (38) < 0.0001 n.s. 
Platelets, x 10
9
/L; median (range) 181 (26-993) 258 (70-632) 123 (38-993) 101 (26-227) < 0.0001 0.03 
 < 100 x 10
9
/L, n (%) 27 (25) 1 (2) 14 (33) 12 (50) < 0.0001 n.s. 
Albumin level, g/L; median (range) 39 (22-48) 41 (30-48) 37 (24-45) 36 (22-43) 0.001 n.s. 
 < 35 g/L, n (%) 28 (26) 3 (7) 15 (35) 10 (42) 0.0002 n.s. 
Alkaline phosphatase, U/L; median (range) 117 (40-1736) 73 (42-387) 135 (40-926) 250 (99-1736) < 0.0001 0.01 
 > 150 U/L, n (%) 44 (41) 5 (12) 19 (44) 20 (83) < 0.0001 0.004 
Ascites, n (%)
#
 37 (34) 1 (2) 18 (42) 18 (75) < 0.0001 0.01 
B-findings       
MC infiltration in BM, %; median (range) 20 (5-95) 10 (5-80) 30 (5-95) 30 (10-95) < 0.0001 n.s 
 > 30 %, n (%) 36 (33) 8 (10) 17 (40) 11 (46) 0.006 n.s. 
Serum tryptase, µg/L; median (range) 127 (13-1854) 49 (4-545) 185 (13-1854) 309 (40-1300) < 0.0001 n.s. 
 > 200 µg/L, n (%) 40 (37) 4 (10) 21 (49) 15 (63) < 0.0001 n.s. 
Spleen volume, mL; median (range)
#
 540 (92-3193) 214 (92-399) 754 (441-1055) 1575 (1210-3193)   
Liver volume, mL; median (range)
#
 2035 (1035-4265) 1647 (1035-2814) 2116 (1167-4265) 2725 (2134-3741) < 0.0001
 
< 0.0001 
 > 2400 mL, n (%) 31 (29) 2 (5) 11 (26) 18 (75) < 0.0001 0.0002 
Lymphadenopathy***
#
 52 (48) 7 (17) 25 (58) 20 (83) < 0.0001 n.s. 
Other relevant findings       
Monocytes, x10
9
/L; median (range) 0.5 (0.1-23.9) 0.4 (0.1-1.8) 0.5 (0.1-23.9) 0.8 (0.2-3.8) 0.003 n.s. 
 > 1 x 10
9
/L, n (%) 23 (21) 1 (2) 14 (33) 8 (33) < 0.0001 n.s. 
Eosinophils, x10
9
/L; median (range) 0.2 (0.0-100.5) 0.1 (0-1.5) 0.6 (0-100.5) 0.3 (0-12.2) < 0.0001 n.s. 
 > 1 x 10
9
/L, n (%) 20 (19) 2 (5) 13 (30) 5 (21) 0.001 n.s. 
KIT D816V
+
 EAB in PB, %; median (range) 22 (1-99) 4 (1-33) 26 (5-65) 38 (10-74) < 0.0001 n.s. 
 > 30 %, n (%) 33 (31) 1 (2) 18 (42) 14 (58) <0.0001 n.s. 
Outcome       
Deaths, n (%) 36 (33) 2 (5) 15 (35) 19 (79)   
2-year OS, % 79 98 74 54 **0.003 **0.005 
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Table 2A: Univariate and multivariate analyses regarding the prognostic impact of clinical and hematological 
characteristics on overall survival of 108 patients with systemic mastocytosis. 
 Univariate Multivariate Prognostic 
Points  HR [95% CI] P* HR [95% CI] P* 
Age ≥ 65 years 4.1 [1.9-9.0] 0.0002    
C-findings
 
     
Cytopenia** 4.5 [2.2-9.2] < 0.0001    
Albumin < 35 g/L 2.7 [1.4-5.2] 0.002    
Alkaline phosphatase > 150 U/L 8.3 [3.4-19.9] < 0.0001 5.2 [2.1-13.0] 0.003 1 
Ascites 3.2 [1.6-6.5] 0.004    
B-findings      
MC infiltration in BM > 30 %  n.s.    
Serum tryptase > 200 µg/L 3.6 [1.7-7.3] 0.0002    
Hepatomegaly > 2400 mL 2.5 [1.3-4.9] 0.007    
Splenomegaly ≥ 450 mL 10.7 [2.6-44.7] < 0.0001 5.0 [1.1-22.2] 0.02 1 
Lymphadenopathy 2.2 [1.1-4.6] 0.03    
Other relevant parameters      
Multi-lineage expansion*** 3.5 [1.8-6.7] < 0.0001    
KIT D816V
+
 EAB in PB > 30% 3.3 [1.7-6.5] 0.0003    
 
 
Table 2B: Univariate and multivariate analyses regarding the prognostic impact of clinical, hematological and 
molecular characteristics on overall survival of 60 patients with advanced systemic mastocytosis.  
 Univariate Multivariate Prognostic 
Points  HR [95% CI] P* HR [95% CI] P* 
Age ≥ 65 years  n.s.    
C-findings
 
     
Cytopenia**  n.s.    
Albumin < 35 g/L  n.s.    
Alkaline phosphatase > 150 U/L 3.6 [1.6-9.3] 0.006 2.6 [1.0-7.1] 0.03 1 
Ascites  n.s.    
B-findings      
MC infiltration in BM > 30 %  n.s.    
Serum tryptase > 200 µg/L  n.s.    
Hepatomegaly > 2400 mL  n.s.    
Splenomegaly ≥ 1200 mL 3.0 [1.4-6.4] 0.002    
Lymphadenopathy  n.s.    
Other relevant parameters      
Multi-lineage expansion***  n.s.    
KIT D816V
+
 EAB in PB > 30%  n.s.    
Mutation in S/A/R  4.3 [1.5-12.4] 0.003 3.2 [1.1-9.6] 0.01 1 
The hazard ratio (HR) is presented together with the 95% confidence interval (CI). *The P-values refer to the log-
rank tests. **Hemoglobin < 10 g/dL and/or platelets < 100 x 10
9
/L. ***Monocytes  > 1 x 10
9
/L and/or eosinophils > 
1 x 10
9
/L. Abbreviations: BM, bone marrow; EAB, expressed allele burden; MC, mast cell; n.s., non-significant; 
PB, peripheral blood, S/A/R, SRSF2/ASXL1/RUNX1 gene panel. 
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Table 3A: Clinical characteristics and outcome of 108 patients with several subtypes of systemic mastocytosis, stratified 
by low, intermediate and high risk based on presence or absence of splenomegaly and/or elevated alkaline 
phosphatase. 
 
Table 3B: Spleen volume characteristics and outcome of 60 patients with advanced systemic mastocytosis, stratified by 
intermediate and high risk based on presence or absence of elevated alkaline phosphatase and/or mutation in 
SRSF2/ASXL1/RUNX1 gene panel. 
*The P-values refer to Fisher’s exact test or the **log-rank test comparing patients with low risk vs. intermediate risk/high 
risk and intermediate risk vs. high risk. **data available in 69% (74/108) of patients. Abbreviations: AHNMD, associated 
hematologic non-mast cell lineage disease; ASM, aggressive SM; ISM; indolent SM; MCL, mast cell leukemia; OS, 
overall survival; SM, systemic mastocytosis; S/A/R, SRSF2/ASXL1/RUNX1 gene panel. 
 
Variables 
All 
patients 
(n = 108) 
Low risk 
(n = 37) 
Inter-
mediate 
risk 
(n = 32) 
High risk 
(n = 39) 
P* 
Low risk vs. 
intermediate 
and high risk 
P* 
Intermediate 
risk vs. high 
risk 
Diagnosis       
ISM, n (%) 41 (37) 32 (87) 9 (28) 0 < 0.0001 0.0003 
ASM, n (%) 5 (5) 2 (5) 2 (6) 1 (3) n.s. n.s. 
MCL, n (%) 7 (6) 0 6 (19) 1 (3) 0.04 0.04 
SM-AHNMD, n (%) 46 (43) 2 (5) 15 (47)  29 (74) < 0.0001 0.001 
MCL-AHNMD, n (%) 9 (8) 1 (3) 0 8 (23) n.s. 0.007 
       
Number of C-findings       
0, n (%) 44 (41) 35 (95) 9 (28) 0 < 0.0001 0.0003 
1, n (%) 22 (20) 2 (5) 16 (50) 4 (10)   
2, n (%) 12 (11) 0 4 (13) 8 (21)   
≥ 3, n (%) 30 (28) 0 3 (9) 27 (69) < 0.0001 < 0.0001 
       
Molecular profile**       
Mutation in S/A/R, n (%) 40 (37) 0 12 (50) 28 (80) < 0.0001 0.01 
Mutation (but not in S/A/R), n (%) 11 (10) 2 (5) 6 (25) 3 (9)   
No mutated gene, n (%) 23 (21) 13 (35) 6 (25) 4 (11) n.s. n.s. 
       
Outcome       
Death, n (%) 36 (33) 0 8 (25) 28 (72)   
2-year OS (%) 77 100 81 56 **0.009 **0.001 
Variables 
All patients 
(n = 60) 
Intermediate 
risk 
(n = 28) 
High risk 
(n = 32) 
P* 
Intermediate risk 
vs. high risk 
Diagnosis     
ASM, n (%) 5 (8) 5 (18) 0 0.02 
MCL, n (%) 6 (10) 6 (21) 0 0.008 
SM-AHNMD, n (%) 40 (67) 15 (54) 25 (78) n.s. 
MCL-AHNMD, n (%) 9 (15) 2 (7) 7 (22) n.s. 
     
Spleen volume     
No splenomegaly (< 450 mL), n (%) 7 (12) 5 (18) 2 (6) n.s. 
Splenomegaly (≥ 450 mL), n (%) 32 (53) 19 (68) 13 (41) 0.04 
Splenomegaly (≥ 1200 mL), n (%) 21 (35) 4 (14) 17 (53) 0.003 
     
Outcome     
Death, n (%) 31 (52) 7 (25) 24 (75)  
2-year OS (%) 65 79 53 **0.0003 
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